Complaint filed in New Jersey alleges Merck uses Halozyme's patented MDASE technology to develop SC Keytruda Halozyme is seeking damages and injunctive relief to stop the infringement SAN DIEGO, April 24, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase for subcutaneous drug delivery, today filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. (Merck) in U.S. District Court in New Jersey. Halozym ...

Core Insights - Halozyme Therapeutics, Inc. announced that argenx received FDA approval for VYVGART® Hytrulo prefilled syringe for self-injection, targeting adult patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [1][2] Group 1: Product Details - VYVGART® Hytrulo is designed for a 20-to-30-second subcutaneous injection, allowing self-administration by patients or caregivers after proper training [2] - The approval is based on studies demonstrating bioequivalence to the vial version of VYVGART® and successful administration by participants in human factors validation studies [2] Group 2: Company Overview - Halozyme is a biopharmaceutical company focused on improving patient experiences through its ENHANZE® drug delivery technology, which facilitates rapid subcutaneous delivery of biologics [3] - The company has impacted over one million patients globally through its technology, which is licensed to major pharmaceutical companies including Roche, Takeda, and Pfizer [3] Group 3: Additional Products and Technologies - Halozyme also develops drug-device combination products using advanced auto-injector technologies aimed at enhancing patient comfort and adherence [4] - The company has two proprietary commercial products, Hylenex® and XYOSTED®, and is engaged in ongoing development with partners like Teva Pharmaceuticals [4]

Subcutaneous DARZALEX® is co-formulated with Halozyme's ENHANZE® drug delivery technologySAN DIEGO, April 9, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval for an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) co-formulated with ENHANZE® in the frontline setting. The approval is for daratumumab SC in combination with bortezomib, lenalidom ...

SAN DIEGO, April 7, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, has received European Commission (EC) marketing authorization of the subcutaneous (SC) formulation of RYBREVANT® (amivantamab), in combination with LAZCLUZE® (lazertinib), for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or e ...

A decision on the European marketing authorization extension for the subcutaneous formulation of Opdivo is expected by June 2, 2025 About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluid ...

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading activities [1]. Group 1 - The website provides general news, personal analysis, and third-party content intended for educational and research purposes [1]. - It explicitly states that the information should not be interpreted as recommendations or advice for any financial actions [1]. - The content is not tailored to individual financial situations or needs, highlighting the necessity for users to perform their own assessments [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - Users are encouraged to understand these instruments fully before engaging in any trading activities [1]. - The website does not provide real-time information and may not guarantee the accuracy of the data presented [1].

Halozyme Therapeutics (HALO) reported fourth-quarter 2024 adjusted earnings of $1.26 per share, which beat the Zacks Consensus Estimate of $1.16. The company had recorded adjusted earnings of 82 cents per share in the year-ago period.See the Zacks Earnings Calendar to stay ahead of market-making news.Total revenues in the fourth quarter increased 30% year over year to $298 million. Revenues surpassed the Zacks Consensus Estimate of $284 million.The top-line growth was primarily driven by higher royalty paym ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communications Helen Torley - President & Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Sean Laaman - Morgan Stanley Brendan Smith - TD Cowen Mohit Bansal - Wells Fargo Jessica Fye - JPMorgan Michael DiFiore - Evercore ISI Jason Butler - Citizens JMP Operator Good afternoon. My n ...

Core Insights - Halozyme Therapeutics reported revenue of $298.01 million for the quarter ended December 2024, marking a year-over-year increase of 29.6% and an EPS of $1.26 compared to $0.82 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $284.02 million, resulting in a surprise of +4.93%, while the EPS also surpassed the consensus estimate of $1.16 with a surprise of +8.62% [1] Revenue Breakdown - Product sales, net amounted to $79.36 million, slightly below the average estimate of $75.16 million, reflecting a year-over-year change of -0.3% [4] - Royalties generated $170.42 million, exceeding the average estimate of $159.68 million, and showing a significant year-over-year increase of +39.6% [4] - Revenues from collaboration agreements reached $48.23 million, slightly below the average estimate of $49.20 million, but representing a substantial year-over-year increase of +69.9% [4] Stock Performance - Over the past month, shares of Halozyme Therapeutics have returned +6.4%, outperforming the Zacks S&P 500 composite's +4.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Group 1 - Halozyme Therapeutics reported quarterly earnings of $1.26 per share, exceeding the Zacks Consensus Estimate of $1.16 per share, and showing an increase from $0.82 per share a year ago, representing an earnings surprise of 8.62% [1] - The company achieved revenues of $298.01 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 4.93%, and up from $230.04 million in the same quarter last year [2] - Halozyme Therapeutics has outperformed the S&P 500, with shares increasing approximately 21.9% since the beginning of the year compared to the S&P 500's gain of 4% [3] Group 2 - The earnings outlook for Halozyme Therapeutics is mixed, with the current consensus EPS estimate for the upcoming quarter at $1.01 on revenues of $247.73 million, and for the current fiscal year at $5.01 on revenues of $1.19 billion [7] - The Medical - Biomedical and Genetics industry, to which Halozyme belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]